Leukemia News

Philip D. Greenberg, MD, FAACR, has been elected American Association for Cancer Research president-elect for 2022-2023.

In the second installment of a three-part video series, Heather Stefanski, MD, PhD, discusses the potential role of umbilical cord blood as a stem cell source.

The FDA granted fast track designation to HM43239 for treatment of certain patients with acute myeloid leukemia.

Black patients appeared consistently underrepresented in pivotal clinical trials that led to FDA approval of several chimeric antigen receptor T-cell therapies, according to findings published in JAMA Network Open.

THOROFARE, NJ — Healio is set to host the inaugural hematology/oncology Disruptive Innovators Award Reception during the American Society of Clinical Oncology Annual Meeting. The event will take place on June 4, 2022, at the Hyatt Regency McCormick Place in Chicago, Illinois.

Younger patients who developed treatment-related hemophagocytic lymphohistiocytosis after tisagenlecleucel infusion for relapsed or refractory B-cell acute lymphoblastic leukemia had significantly poorer outcomes, according to study results.

Click here to read the Cover Story, “ Pandemic proves telehealth ‘works in saving lives’ and ‘that we have an inequitable system’ ”

The FDA granted regenerative medicine advanced therapy designation to obecabatagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Fludarabine exposure appeared associated with improved clinical outcomes among pediatric patients undergoing chimeric antigen receptor T-cell therapy for refractory or relapsed B-cell acute lymphoblastic leukemia, study results showed.

SALT LAKE CITY — Zanubrutinib improved outcomes compared with bendamustine/rituximab among adults with treatment-naive deletion 17p-negative chronic lymphocytic leukemia or small lymphocytic lymphoma, according to phase 3 study results.